Diagnosis and management of multiple myeloma: a review
Importance Multiple myeloma is a hematologic malignancy characterized by presence of
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
P Moreau, SK Kumar, J San Miguel, F Davies… - The Lancet …, 2021 - thelancet.com
Summary This Policy Review presents the International Myeloma Working Group's clinical
practice recommendations for the treatment of relapsed and refractory multiple myeloma …
practice recommendations for the treatment of relapsed and refractory multiple myeloma …
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
SV Rajkumar - American journal of hematology, 2022 - Wiley Online Library
Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …
Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal …
Background On the basis of the DREAMM‐2 study (ClinicalTrials. gov identifier
NCT03525678), single‐agent belantamab mafodotin (belamaf) was approved for patients …
NCT03525678), single‐agent belantamab mafodotin (belamaf) was approved for patients …
Bispecific antibodies in multiple myeloma: present and future
G Lancman, DL Sastow, HJ Cho, S Jagannath… - Blood cancer …, 2021 - AACR
Despite many recent advances in therapy, there is still no plateau in overall survival curves
in multiple myeloma. Bispecific antibodies are a novel immunotherapeutic approach …
in multiple myeloma. Bispecific antibodies are a novel immunotherapeutic approach …
Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy
Almost all patients with multiple myeloma (MM) will eventually develop disease that has
relapsed with or become refractory to available treatments and will require additional …
relapsed with or become refractory to available treatments and will require additional …
Small molecule inhibitors targeting the cancers
Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …
Relapsed/refractory multiple myeloma in 2020/2021 and beyond
K Podar, X Leleu - Cancers, 2021 - mdpi.com
Simple Summary During the last two decades, collaborative translational studies utilizing
novel methodologies have dramatically advanced our understanding of multiple myeloma …
novel methodologies have dramatically advanced our understanding of multiple myeloma …
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee
A wide variety of new therapeutic options for Multiple Myeloma (MM) have recently become
available, extending progression-free and overall survival for patients in meaningful ways …
available, extending progression-free and overall survival for patients in meaningful ways …
[HTML][HTML] Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo
T Kashyap, J Murray, CJ Walker, H Chang, S Tamir… - Antiviral Research, 2021 - Elsevier
The novel coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) is responsible for the recent global pandemic. The …
syndrome coronavirus 2 (SARS-CoV-2) is responsible for the recent global pandemic. The …